Initial Investment In Relief Therapeutics SA Announced By Global Emerging Markets

Global Emerging Markets Announces Initial Investment in Relief Therapeutics SA.Atexakin alfa is an experimental drug ready to enter clinical testing in patients addressing an unmet medical need in diabetic neuropathy (“DN”). Currently, no similar drugs are approved, while the market for DN-related drugs is expected to increase to USD 4.1 billion by 2019.

More:
www.businesswire.com/news/home/20160523005147/en/Global-Emerging-Markets-Announces-Initial-Investment-Relief